Clinical Trial Update: Methylene Blue for Cognitive Dysfunction in Bipolar Disorder [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating methylene blue for cognitive dysfunction in bipolar disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• METHYLENE BLUE (METHYLENE BLUE)

Snippet

Sponsor: Nova Scotia Health Authority | Conditions: Bipolar Disorder | Phase 3 | Status: COMPLETED